Torsten Falk, PhD, University of Arizona, Tuscon, AZ, comments on the potential long term effects of low-dose ketamine to in patients with levodopa-induced dyskinesia. Existing data in the mental health field has yielded promising results, where patients with treatment-resistant depression do not have negative outcomes in multiple Phase II/III trials. Additional studies are required if this is true in patients with Parkinson’s disease. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved